Índice
Literatura académica sobre el tema "Philip Johnson Associates"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Philip Johnson Associates".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Philip Johnson Associates"
Chohan, S., A. Kavanaugh, V. Strand, R. C. Chou, A. M. Mendelsohn, S. Rozzo y P. J. Mease. "AB0803 EFFICACY OF TILDRAKIZUMAB IN PsA: DAS28-CRP SCORES THROUGH WEEK 52". Annals of the Rheumatic Diseases 79, Suppl 1 (junio de 2020): 1702–3. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3907.
Texto completoJayne, D., P. Gavin, E. Allman, C. Di Poto, X. Tian, S. Hess, M. Ramaswamy et al. "OP0136 METABOLOMIC SERUM PROFILING IDENTIFIES METABOLITES LINKED TO KIDNEY DAMAGE WHICH ARE MODULATED BY ANIFROLUMAB IN A PHASE 2 TRIAL IN LUPUS NEPHRITIS". Annals of the Rheumatic Diseases 82, Suppl 1 (30 de mayo de 2023): 90.1–90. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1569.
Texto completoPray, C., N. Narula, E. C. Wong, J. K. Marshall, S. Rangarajan, S. Islam, A. Bahonar et al. "A176 ASSOCIATIONS OF ANTIBIOTICS, HORMONAL THERAPIES, ORAL CONTRACEPTIVES, AND LONG-TERM NSAIDS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE PROSPECTIVE URBAN RURAL EPIDEMIOLOGY (PURE) STUDY". Journal of the Canadian Association of Gastroenterology 6, Supplement_1 (1 de marzo de 2023): 20–22. http://dx.doi.org/10.1093/jcag/gwac036.176.
Texto completoRahman, P., C. T. Ritchlin, P. Helliwell, W. H. Boehncke, P. J. Mease, A. B. Gottlieb, S. Kafka et al. "FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS". Annals of the Rheumatic Diseases 79, Suppl 1 (junio de 2020): 776–77. http://dx.doi.org/10.1136/annrheumdis-2020-eular.387.
Texto completoRahman, P., P. J. Mease, A. Deodhar, A. Kavanaugh, S. D. Chakravarty, A. Kollmeier, Y. Liu, M. Shawi y C. Han. "OP0025 FACTORS ASSOCIATED WITH FATIGUE AND ITS IMPROVEMENT – A PRINCIPAL COMPONENT ANALYSIS OF PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS FROM GUSELKUMAB PHASE 3 TRIALS". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de mayo de 2022): 18–19. http://dx.doi.org/10.1136/annrheumdis-2022-eular.895.
Texto completoCoates, L. C., C. T. Ritchlin, L. Gossec, P. Helliwell, P. Rahman, E. C. Hsia, A. Kollmeier et al. "POS1024 GUSELKUMAB PROVIDES SUSTAINED DOMAIN-SPECIFIC AND COMPREHENSIVE EFFICACY AS ASSESSED USING COMPOSITE ENDPOINTS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de mayo de 2021): 781–82. http://dx.doi.org/10.1136/annrheumdis-2021-eular.167.
Texto completoCurtis, J., I. Mcinnes, D. D. Gladman, F. Yang, S. Peterson, P. Agarwal, A. Kollmeier et al. "POS1028 PATIENT CHARACTERISTICS & CLINICAL FEATURES ASSOCIATE WITH HEALTH-RELATED QUALITY OF LIFE IN BIO-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH WEEK 24 OF THE DISCOVER-2 STUDY". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de mayo de 2021): 784–85. http://dx.doi.org/10.1136/annrheumdis-2021-eular.432.
Texto completoCoates, L., J. Ramírez, D. Mcgonagle, S. Aydin, M. Zimmermann, F. Nantel, M. Shawi, E. Rampakakis, P. Nash y P. J. Mease. "POS1540 EARLY SKIN AND EARLY ENTHESITIS RESPONSES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB ASSOCIATE WITH LONG-TERM RESPONSE: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3 STUDY". Annals of the Rheumatic Diseases 82, Suppl 1 (30 de mayo de 2023): 1137.1–1137. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2581.
Texto completoMcgonagle, D., I. Mcinnes, A. Deodhar, G. Schett, P. J. Mease, M. Shawi, S. Kafka et al. "AB0801 EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES". Annals of the Rheumatic Diseases 79, Suppl 1 (junio de 2020): 1701.2–1701. http://dx.doi.org/10.1136/annrheumdis-2020-eular.836.
Texto completoCurtis, J., I. McInnes, P. Rahman, D. D. Gladman, F. Yang, S. Peterson, A. Kollmeier et al. "AB0881 Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de mayo de 2022): 1563.2–1564. http://dx.doi.org/10.1136/annrheumdis-2022-eular.733.
Texto completoLibros sobre el tema "Philip Johnson Associates"
Architecture's odd couple: Frank Lloyd Wright and Philip Johnson. 2016.
Buscar texto completo